Chronic kidney disease complicated with mixed dyslipidemia
Conditions
Interventions
The group treated with Zhibite combined with atorvastatin:Based on the control group, Lipitai Capsules were added, 480mg each time, twice a day, orally. The treatment was maintained until the end.
Atorvastatin group:Atorvastatin Calcium Tablets, 10mg each time, once a day, oral administration, for maintenance treatment until the end.
Sponsors
Zhengzhou Central Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Chronic kidney disease (CKD) combined with mixed dyslipidemia: triglyceride (TG) >= 2.3 mmol/L, low-density lipoprotein cholesterol (LDL-C) >= 3.4 mmol/L. 2. In the past 2 weeks, no other drugs affecting lipid metabolism have been taken. 3. The patient and his/her family members have been informed and signed the consent form.
Exclusion criteria
Exclusion criteria: 1. Those who are allergic to the drug under study; 2. Patients with active liver diseases or with persistent elevation of aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) for no apparent reason; 3. Pregnant women and lactating women; 4. Patients with acute infections in other parts such as peritonitis, urinary tract infection, pneumonia, etc.; 5. Patients with severe cardiovascular or cerebrovascular diseases; 6. Patients with malignant tumors, mental disorders, etc.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of various lipid indicators: TG, TC, LDL-C, HDL-C, ApoA1, ApoB, Lp(a); | — |
Countries
China
Contacts
Public Contacthemeng
Zhengzhou Central Hospital
Outcome results
None listed